Another study has determined the proportion of people with T2D that met inclusion criteria for each of three SGLT2 inhibitor kidney outcome trials (CREDENCE, DAPA-CKD and EMPA-KIDNEY) within the US population [10]. Here, SLC5A2 is linked to chronic kidney disease.